Robert Browne
Director of Finance/CFO at Viron Therapeutics, Inc.
Robert Browne active positions
| Companies | Position | Start | End |
|---|---|---|---|
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Director of Finance/CFO | - | - |
Career history of Robert Browne
Former positions of Robert Browne
| Companies | Position | Start | End |
|---|---|---|---|
| TELESTA THERAPEUTICS INC | Director of Finance/CFO | - | - |
| FENNEC PHARMACEUTICALS INC. | Director of Finance/CFO | - | - |
The Canadian Institute of Chartered Accountants
 The Canadian Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services Canadian Institute of Chartered Accountants engages in the provision of accounting, auditing, tax, advisory, and professional services. The institute is headquartered in Toronto, Canada. | Corporate Officer/Principal | - | - |
Statistics
International
| Canada | 4 |
| United States | 2 |
Operational
| Director of Finance/CFO | 3 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| Private companies | 3 |
|---|---|
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
The Canadian Institute of Chartered Accountants
The Canadian Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services Canadian Institute of Chartered Accountants engages in the provision of accounting, auditing, tax, advisory, and professional services. The institute is headquartered in Toronto, Canada. | Commercial Services |
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
- Stock Market
- Insiders
- Robert Browne
- Experience
